{
  "schemaVersion": 1,
  "id": "research-311",
  "slug": "311-why-triumph-2-enrolled-adults-with-type-2-diabetes",
  "title": "Why TRIUMPH-2 enrolled adults with type 2 diabetes",
  "catalogLabel": "RETA GLP-3",
  "productCollection": "https://heritagebiolabs.com/research-library/products/reta-glp-3",
  "productHandles": [
    "reta-glp-3-689",
    "reta-glp-3-690",
    "reta-glp-3-705",
    "reta-glp-3-706"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/reta-glp-3-689",
    "https://heritagebiolabs.com/product/reta-glp-3-690",
    "https://heritagebiolabs.com/product/reta-glp-3-705",
    "https://heritagebiolabs.com/product/reta-glp-3-706"
  ],
  "readingFocus": "Study findings",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 392,
  "sourceYears": [
    2026
  ],
  "paragraphs": [
    "Peptides are short chains of amino acids linked by peptide bonds. Some influence the body’s response to nutrients by engaging receptors. Retatrutide is an investigational peptide that activates GIP, GLP-1 and glucagon receptors. “GLP-3” is catalog wording for this triple agonist. The 2026 TRIUMPH-2 report asked what happened to body weight in participants who had both type 2 diabetes and excess body weight. [1]",
    "The investigators enrolled adults at 92 centers in eight countries. Participants had type 2 diabetes and were already on stable diabetes management. Most were using an oral glucose-lowering medicine at the start. The researchers randomized 1,152 people to one of three retatrutide groups or placebo. In this setting, the comparison includes the role of that stable background care. A trial that enrolled only people whose diabetes was managed with lifestyle measures would have a different starting population. [1]",
    "The primary comparison looked at the percentage change in body weight from baseline to week 80 in two retatrutide groups versus placebo. Under the analysis that reflected treatment assignment, estimated average changes were −16.8% and −18.8% for the two main active groups and −5.1% for placebo. The third active group had an estimated average change of −11.9%. The study also reported blood sugar measures and safety outcomes. Group assignment, adherence and missing measurements all help determine what a trial estimate means. The report explains how missing data were estimated for the primary analysis. [1]",
    "About 84% of randomized participants completed treatment with the study drug. A result based on assignment gives a broader view than an average calculated only for people who finished treatment exactly as planned. The study still describes a population that was eligible for this protocol and followed in a controlled setting. People with different diabetes histories or treatments could have different responses, and clinical decisions require more than the group average. [1]",
    "The separate TRIUMPH-1 trial focused on people without diabetes. Its results can be read beside TRIUMPH-2 to learn about the populations the research program examined. A difference between reported percentages across the two trials cannot isolate the effect of having diabetes, because participants were randomized within each trial and not across the two populations. TRIUMPH-2 provides the randomized comparison of retatrutide and placebo for its enrolled adults with type 2 diabetes. The approval status remains a separate question from this trial’s results. [1, 2]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Virginia Bellido et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet (publication 2026-09-29).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42810372/"
    },
    {
      "number": 2,
      "citation": "Ania M. Jastreboff et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. The New England Journal of Medicine (publication 2026-09-29).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42814954/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/311-why-triumph-2-enrolled-adults-with-type-2-diabetes",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/311-why-triumph-2-enrolled-adults-with-type-2-diabetes.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/311-why-triumph-2-enrolled-adults-with-type-2-diabetes.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 063 - RETA GLP-3 and RETA IGF-1 LR3.docx",
    "sourceArticleNumber": 311,
    "contentSha256": "0463a9253c577440c7ea552442eb370d49358d704ed2a0287d58ffcf0bdac1e9",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
